Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of JNJ-77242113 in moderate-to-severe plaque psoriasis
ISRCTN15135908Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2022
- Modality
- Peptides
01
Overview
Phase 2, double-blind trial of icotrokinra in plaque psoriasis (6 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Percentage of participants achieving PASI 75 at Week 36. Started Jun 2022; status: completed.
02
Drugs
icotrokinra
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on ISRCTN15135908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN15135908.